ApoE facilitates the microglial response to amyloid plaque pathology
Open accessThe DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index.
Abstract
One of the hallmarks of Alzheimer’s disease is the presence of extracellular diffuse and fibrillar plaques predominantly consisting of the amyloid-β (Aβ) peptide. Apolipoprotein E (ApoE) influences the deposition of amyloid pathology through affecting the clearance and aggregation of monomeric Aβ in the brain. In addition to influencing Aβ metabolism, increasing evidence suggests that apoE influences microglial function in neurodegenerative diseases. Here, we characterize the impact that apoE has on amyloid pathology and the innate immune response in APPPS1ΔE9 and APPPS1-21 transgenic mice. We report that Apoe deficiency reduced fibrillar plaque deposition, consistent with previous studies. However, fibrillar plaques in Apoe-deficient mice exhibited a striking reduction in plaque compaction. Hyperspectral fluorescent imaging using luminescent conjugated oligothiophenes identified distinct Aβ morphotypes in Apoe-deficient mice. We also observed a significant reduction in fibrillar plaque–associated microgliosis and activated microglial gene expression in Apoe-deficient mice, along with significant increases in dystrophic neurites around fibrillar plaques. Our results suggest that apoE is critical in stimulating the innate immune response to amyloid pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3. Decreased plaque-associated microgliosis in Apoe-deficient mice. (A) Representative images of APPPS1 and Apoe−/−;APPPS1 mice stained with Iba1 to label microglia and X-34 to label amyloid plaques. (B) Significant reduction in the number of microglia in Apoe−/−;APPPS1 (0.60 ± 0.04, n = 7 mice) mice compared with APPPS1 (1.7 ± 0.12, n = 7) within 15 µm (t[12] = 8.3, P < 0.0001) and 30 µm (2.5 ± 0.18, n = 7 mice versus 4.5 ± 0.28, n = 7 mice); t(12) = 5.9, P < 0.0001, Student’s t test. The number of microglia >30 µm from a plaque in APPPS1 (154.3 ± 7.1, n = 7 mice) compared with Apoe−/−;APPPS1 (150.7 ± 14.9, n = 7 mice) was not significantly different; t(12) = 0.22, P = 0.83, Student’s t test. (C) Representative images of APPPS1ΔE9 and Apoe−/−;APPPS1ΔE9 mice stained with Iba1 and X-34. (D) Significant reduction in the number of microglia within 15 µm of Apoe−/−;APPPS1ΔE9 (1.2 ± 0.17, n = 7 mice), compared with APPPS1ΔE9 (2.2 ± 0.1, n = 11 mice); t(16) =5.6, P < 0.0001, Student’s t test, and within 30 µm (2.8 ± 0.24, n = 7 mice) compared with (4.6 ± 0.16, n = 11 mice); t(16) = 6.5, P < 0.0001, Student’s t test. The number of microglia >30 µm from a plaque in APPPS1ΔE9 (160.3 ± 14.7, n = 11 mice) and Apoe−/−;APPPS1ΔE9 (133.2 ± 8.5, n = 7 mice) were not significantly different; t(16) = 1.4, P = 0.19, Student’s t test. (E) Selected differentially expressed inflammatory gene expression from APPPS1 (n = 6 mice) and Apoe−/−;APPPS1 mice (n = 7 mice). See Table S1 for p-values. (F) Analysis of cytokine levels in the hippocampus of APPPS1 and Apoe−/−;APPPS1 mice. Apoe−/−;APPPS1 mice (n = 13 mice) exhibited a significant reduction in CCL3 compared with APPPS1 mice (n = 11 mice). P < 0.0001, Student’s t test. Bars, 100 µm. ***, P < 0.001.](https://figures.cochat.ai/paper-figures/18ed3f387eff4ebda9af8d5233d33033/apoe-facilitates-the-microglial-response-to-amyloid-plaque-pathology-figure-3.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies have shown that neurites surrounding amyloid plaques are enriched in the lysosomal marker, lysosome-associated membrane protein 1 (LAMP1) in both human patients with dementia and mouse models of AD29,30.”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“as TREM2 has been demonstrated to be an ApoE receptor116–119.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Microglia form a critical interface between APOE genotype and amyloid pathology, mediating A β clearance and restricting local toxicity 25,40 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ApoE also markedly accelerates amyloid deposition (23,24) as well as taumediated neurodegeneration in mouse models (25).”
From Regulation of astrocyte lipid metabolism and ApoE secretion by the microglial oxysterol, 25-hydroxycholesterol (2023) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies showed that apoE is co-deposited in senile plaques and plays a crucial role in fibrillar plaque formation (23, 24).”
From APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia (2021) · cites this paper as [24]
Experimental — accuracy not yet measured
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493 · cited 2×
“3 G; Table S1; Keren-Shaul et al., 2017).”
Self-citationTREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 1×
“Variants in microglial-expressed genes, such as TREM2 and CD33 alter the risk of developing AD, implicating the importance of microglia in the onset and progression of AD (Naj et al., 2011; Griciuc et al., 2013; Guerreiro et al., 2013; Jonsson et al., 2013).”
Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979 · cited 3×
“However, beyond its effect on amyloid, apoE also influences diverse processes in the brain, such as synaptogenesis, phagocytosis, BBB function, and microglial activation (Mauch et al., 2001; Bell et al., 2012; Butovsky et al., 2015; Chung et al., 2016; Krasemann et al., 2017; Shi et al., 2017).”
Self-citationVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 1×
“Variants in microglial-expressed genes, such as TREM2 and CD33 alter the risk of developing AD, implicating the importance of microglia in the onset and progression of AD (Naj et al., 2011; Griciuc et al., 2013; Guerreiro et al., 2013; Jonsson et al., 2013).”
Identification of a unique TGF-β–dependent molecular and functional signature in microglia
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3599 · Cited by 2,543 · cited 1×
“ApoE expression is low in microglia in a homeostatic activation state, but is strongly up-regulated by neurodegenerative insults (Butovsky et al., 2014, 2015; Krasemann et al., 2017).”
Naj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901 · cited 1×
“Variants in microglial-expressed genes, such as TREM2 and CD33 alter the risk of developing AD, implicating the importance of microglia in the onset and progression of AD (Naj et al., 2011; Griciuc et al., 2013; Guerreiro et al., 2013; Jonsson et al., 2013).”
TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model
Wang, Y., Cella, M., Mallinson, K., Ulrich, J. D., Young, K. L., Robinette, M. L., Gilfillan, S., Krishnan, G. M., Sudhakar, S., Zinselmeyer, B. H., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.049 · Cited by 1,736 · cited 1×
“…plaque morphology and increased neuritic dystrophy, suggestive of a role for microglia in shaping the gross structure of plaques and reducing plaque-associated toxicity (Ulrich et al., 2014; Wang et al., 2015, 2016; Yuan et al., 2016; Jay et al., 2017; Song et al., 2017; Ulland et al., 2017).”
Self-citationCNS synaptogenesis promoted by glia-derived cholesterol
Mauch, D. H., Nägler, K., Schumacher, S., Göritz, C., Müller, E.-C., Otto, A., & Pfrieger, F. W. (2001) · Science · doi:10.1126/science.294.5545.1354 · Cited by 1,711 · cited 1×
“However, beyond its effect on amyloid, apoE also influences diverse processes in the brain, such as synaptogenesis, phagocytosis, BBB function, and microglial activation (Mauch et al., 2001; Bell et al., 2012; Butovsky et al., 2015; Chung et al., 2016; Krasemann et al., 2017; Shi et al., 2017).”
Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575 · cited 2×
“Tg2576 mice exhibited a roughly 1:5 ratio of Aβ42/Aβ40 in young animals, compared with an ∼1:1 ratio in APP PS1 and APP PS1ΔE9 mice, which likely results in the accelerated development of Aβ-deposition in APP PS1 and APP PS1ΔE9 mice and the formation of amyloid (Jankowsky et al., 2004; Radde et al., 2006).”
Single App knock-in mouse models of Alzheimer’s disease
Saito, T., Matsuba, Y., Mihira, N., Takano, J., Nilsson, P., Itohara, S., Iwata, N., & Saido, T. C. (2014) · Nature Neuroscience · doi:10.1038/nn.3697 · Cited by 1,366 · cited 2×
“20171265 1053 provide additional insight into potential mechanisms underlying our observations (Saito et al., 2014).”
InfluentialApolipoprotein E controls cerebrovascular integrity via cyclophilin A
Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., Holtzman, D. M., Betsholtz, C., Armulik, A., Sallstrom, J., et al. (2012) · Nature · doi:10.1038/nature11087 · Cited by 1,293 · cited 2×
“However, beyond its effect on amyloid, apoE also influences diverse processes in the brain, such as synaptogenesis, phagocytosis, BBB function, and microglial activation (Mauch et al., 2001; Bell et al., 2012; Butovsky et al., 2015; Chung et al., 2016; Krasemann et al., 2017; Shi et al., 2017).”
Self-citationTREM2 Maintains Microglial Metabolic Fitness in Alzheimer’s Disease
Ulland, T. K., Song, W. M., Huang, S. C.-C., Ulrich, J. D., Sergushichev, A., Beatty, W. L., Loboda, A. A., Zhou, Y., Cairns, N. J., Kambal, A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.023 · Cited by 1,263 · cited 2×
“20171265 1048 reduced plaque-associated microgliosis, and Trem2-deficient mice exhibit altered plaque morphology and increased neuritic dystrophy, suggestive of a role for microglia in shaping the gross structure of plaques and reducing plaque-associated toxicity (Ulrich et al., 2014; Wang et al., 2015, 2016; Yuan et…”
Self-citationApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy
Initiative, A. D. N., Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., Tsai, R. M., Spina, S., Grinberg, L. T., et al. (2017) · Nature · doi:10.1038/nature24016 · Cited by 1,220 · cited 2×
“However, beyond its effect on amyloid, apoE also influences diverse processes in the brain, such as synaptogenesis, phagocytosis, BBB function, and microglial activation (Mauch et al., 2001; Bell et al., 2012; Butovsky et al., 2015; Chung et al., 2016; Krasemann et al., 2017; Shi et al., 2017).”
Self-citationAlzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta
Griciuc, A., Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., Hooli, B., Choi, S. H., Hyman, B. T., & Tanzi, R. E. (2013) · Neuron · doi:10.1016/j.neuron.2013.04.014 · Cited by 1,004 · cited 1×
“Variants in microglial-expressed genes, such as TREM2 and CD33 alter the risk of developing AD, implicating the importance of microglia in the onset and progression of AD (Naj et al., 2011; Griciuc et al., 2013; Guerreiro et al., 2013; Jonsson et al., 2013).”
Self-citationAβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M. E., Jäggi, F., Wolburg, H., Gengler, S., et al. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400784 · Cited by 986 · cited 5×
“…transgenic mice on a C57BL6 background containing the APP KM670/671NL Swedish mutations and PSEN1 L166P mutation (gift from M. Jucke, University of Tübingen, Tübingen, Germany; Radde et al., 2006) were crossed with Apoe−/− mice on a C57BL6 background (Jackson Labs) to produce Apoe+/−;APP PS1 mice.”
InfluentialYeh, F. L., Wang, Y., Tom, I., Gonzalez, L. C., & Sheng, M. (2016) · Neuron · doi:10.1016/j.neuron.2016.06.015 · Cited by 943 · cited 1×
“Interestingly, lipidated apoE binds to TREM2 in vitro and may be a potential physiological ligand mediating TREM2 activation (Atagi et al., 2015; Yeh et al., 2016).”
Self-citationInnate immunity in Alzheimer's disease
Heneka, M. T., Golenbock, D. T., & Latz, E. (2015) · Nature Immunology · doi:10.1038/ni.3102 · Cited by 902
Neutrophils promote Alzheimer's disease–like pathology and cognitive decline via LFA-1 integrin
Zenaro, E., Pietronigro, E., Bianca, V. D., Piacentino, G., Marongiu, L., Budui, S., Turano, E., Rossi, B., Angiari, S., Dusi, S., et al. (2015) · Nature Medicine · doi:10.1038/nm.3913 · Cited by 865 · cited 1×
“Moreover, a compromised BBB could lead to increased infiltration of peripheral macrophages and neutrophils into the brain, which may also be neurotoxic (Zenaro et al., 2015).”
TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques
Wang, Y., Ulland, T. K., Ulrich, J. D., Song, W., Tzaferis, J. A., Hole, J. T., Yuan, P., Mahan, T. E., Shi, Y., Gilfillan, S., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151948 · Cited by 840 · cited 1×
“Interestingly, lipidated apoE binds to TREM2 in vitro and may be a potential physiological ligand mediating TREM2 activation (Atagi et al., 2015; Yeh et al., 2016).”
Self-citationMicroglia: Scapegoat, saboteur, or something else?
Aguzzi, A., Barres, B. A., & Bennett, M. L. (2013) · Science · doi:10.1126/science.1227901 · Cited by 836
Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-263 · Cited by 830
Yuan, P., Condello, C., Keene, C. D., Wang, Y., Bird, T. D., Paul, S. M., Luo, W., Colonna, M., Baddeley, D., & Grutzendler, J. (2016) · Neuron · doi:10.1016/j.neuron.2016.05.003 · Cited by 817 · cited 3×
“20171265 1048 reduced plaque-associated microgliosis, and Trem2-deficient mice exhibit altered plaque morphology and increased neuritic dystrophy, suggestive of a role for microglia in shaping the gross structure of plaques and reducing plaque-associated toxicity (Ulrich et al., 2014; Wang et al., 2015, 2016; Yuan et…”
Self-citationapoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771 · cited 1×
“ApoE has previously been shown to influence the rate of monomeric Aβ clearance from the brain interstitial fluid in an isoform-dependent manner and to influence the kinetics of amyloid formation in vitro (Bell et al., 2007; Deane et al., 2008; Huynh et al., 2017a).”
Self-citationMicroglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques
Condello, C., Yuan, P., Schain, A., & Grutzendler, J. (2015) · Nature Communications · doi:10.1038/ncomms7176 · Cited by 718 · cited 5×
“Plaque-associated dystrophic neurites appear in areas devoid of microglial coverage, suggesting that microglia may limit amyloid toxicity in plaque-adjacent neurons (Condello et al., 2015).”
InfluentialBell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., & Zlokovic, B. V. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600419 · Cited by 670 · cited 1×
“ApoE has previously been shown to influence the rate of monomeric Aβ clearance from the brain interstitial fluid in an isoform-dependent manner and to influence the kinetics of amyloid formation in vitro (Bell et al., 2007; Deane et al., 2008; Huynh et al., 2017a).”
Self-citationThree dimensions of the amyloid hypothesis: time, space and 'wingmen'
Musiek, E. S., & Holtzman, D. M. (2015) · Nature Neuroscience · doi:10.1038/nn.4018 · Cited by 662 · cited 2×
“Aβ42 exhibits a greater propensity to form amyloid fibrils, and variants in APP, PSEN1, or PSEN2 that increase the production of Aβ42 relative to shorter Aβ species result in autosomal dominant AD (Musiek and Holtzman, 2015).”
Self-citationApolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2)
Atagi, Y., Liu, C.-C., Painter, M. M., Chen, X.-F., Verbeeck, C., Zheng, H., Li, X., Rademakers, R., Kang, S. S., Xu, H., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.679043 · Cited by 587 · cited 1×
“Interestingly, lipidated apoE binds to TREM2 in vitro and may be a potential physiological ligand mediating TREM2 activation (Atagi et al., 2015; Yeh et al., 2016).”
Murine tumor necrosis factor alpha is transported from blood to brain in the mouse
Gutierrez, E. G., Banks, W. A., & Kastin, A. J. (1993) · Journal of Neuroimmunology · doi:10.1016/0165-5728(93)90027-v · Cited by 577 · cited 1×
“This may be attributable to increases in peripheral TNF-α expression in Apoe−/− mice, since TNF-α is transported across the blood–brain barrier (BBB; Gutierrez et al., 1993; Grainger et al., 2004).”
Bales, K. R., Verina, T., Cummins, D. J., Du, Y., Dodel, R. C., Saura, J., Fishman, C. E., DeLong, C. A., Piccardo, P., Petegnief, V., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15233 · Cited by 486 · cited 1×
“Previous studies in human APP transgenic mice, PDA PP and Tg2576, found that Apoe deficiency significantly reduced both total and fibrillar Aβ deposition (Bales et al., 1997, 1999; Holtzman et al., 2000; Irizarry et al., 2000).”
Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer's Disease
Jay, T. R., Hirsch, A. M., Broihier, M. L., Miller, C. M., Neilson, L. E., Ransohoff, R. M., Lamb, B. T., & Landreth, G. E. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2110-16.2016 · Cited by 457 · cited 2×
“20171265 1048 reduced plaque-associated microgliosis, and Trem2-deficient mice exhibit altered plaque morphology and increased neuritic dystrophy, suggestive of a role for microglia in shaping the gross structure of plaques and reducing plaque-associated toxicity (Ulrich et al., 2014; Wang et al., 2015, 2016; Yuan et…”
ApoE4 Accelerates Early Seeding of Amyloid Pathology
Liu, C.-C., Zhao, N., Fu, Y., Wang, N., Linares, C., Tsai, C.-W., & Bu, G. (2017) · Neuron · doi:10.1016/j.neuron.2017.11.013 · Cited by 451 · cited 1×
“Recent studies indicate that apoE expression influences the initiation of fibrillar plaque deposition, but not the subsequent growth of amyloid plaques once plaque formation has occurred (Huynh et al., 2017b; Liu et al., 2017).”
Apolipoprotein E, Receptors, and Modulation of Alzheimer’s Disease
Zhao, N., Liu, C.-C., Qiao, W., & Bu, G. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.03.003 · Cited by 370 · cited 1×
“Within the brain, apoE is predominantly expressed by astrocytes, although microglia, particularly in an activated state, also produce apoE (Zhao et al., 2018).”
Targeting mi R‐155 restores abnormal microglia and attenuates disease in SOD 1 mice
Butovsky, O., Jedrychowski, M. P., Cialic, R., Krasemann, S., Murugaiyan, G., Fanek, Z., Greco, D. J., Wu, P. M., Doykan, C. E., Kiner, O., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24304 · Cited by 358 · cited 4×
“However, beyond its effect on amyloid, apoE also influences diverse processes in the brain, such as synaptogenesis, phagocytosis, BBB function, and microglial activation (Mauch et al., 2001; Bell et al., 2012; Butovsky et al., 2015; Chung et al., 2016; Krasemann et al., 2017; Shi et al., 2017).”
InfluentialHoltzman, D. M., Bales, K. R., Wu, S., Bhat, P., Parsadanian, M., Fagan, A. M., Chang, L. K., Sun, Y., & Paul, S. M. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6179 · Cited by 349 · cited 2×
“…studies found that genetic deletion of Apoe in amyloid-depositing mouse models overexpressing human amyloid precursor protein (APP), but not PS1, resulted in a dramatic decrease in diffuse plaques and an absence of fibrillar plaque formation (Bales et al., 1997; Holtzman et al., 1999, 2000).”
Self-citationUntangling the brain’s neuroinflammatory and neurodegenerative transcriptional responses
Srinivasan, K., Friedman, B. A., Larson, J. L., Lauffer, B. E., Goldstein, L. D., Appling, L. L., Borneo, J., Poon, C., Ho, T., Cai, F., et al. (2016) · Nature Communications · doi:10.1038/ncomms11295 · Cited by 336 · cited 2×
“…in microglial gene expression in amyloid models detected using whole tissue methods may result from either the up-regulation of a given transcript at the cellular level or an increase in microglial abundance, which, in general, positively correlates with amyloid burden (Srinivasan et al., 2016).”
Altered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2
Ulrich, J. D., Finn, M. B., Wang, Y., Shen, A., Mahan, T. E., Jiang, H., Stewart, F. R., Piccio, L., Colonna, M., & Holtzman, D. M. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-20 · Cited by 302 · cited 2×
“20171265 1048 reduced plaque-associated microgliosis, and Trem2-deficient mice exhibit altered plaque morphology and increased neuritic dystrophy, suggestive of a role for microglia in shaping the gross structure of plaques and reducing plaque-associated toxicity (Ulrich et al., 2014; Wang et al., 2015, 2016; Yuan et…”
Self-citationSong, W., Hooli, B., Mullin, K., Jin, S. C., Cella, M., Ulland, T. K., Wang, Y., Tanzi, R. E., & Colonna, M. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.07.004 · Cited by 297 · cited 2×
“20171265 1048 reduced plaque-associated microgliosis, and Trem2-deficient mice exhibit altered plaque morphology and increased neuritic dystrophy, suggestive of a role for microglia in shaping the gross structure of plaques and reducing plaque-associated toxicity (Ulrich et al., 2014; Wang et al., 2015, 2016; Yuan et…”
Self-citationFagan, A. M., Watson, M., Parsadanian, M., Bales, K. R., Paul, S. M., & Holtzman, D. M. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0483 · Cited by 290 · cited 1×
“We found that Apoe-deficient mice exhibited reduced fibrillar plaque deposition and altered regional distribution of plaque pathology within the hippocampus, consistent with previous studies (Holtzman et al., 1999; Irizarry et al., 2000; Fagan et al., 2002).”
Self-citationStyren, Hamilton, R. L., Styren, G. C., & Klunk, W. E. (2000) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215540004800906 · Cited by 290 · cited 1×
“Given that we observed significant levels of Aβ plaque pathology in both APP PS1 and APP PS1ΔE9 mice in the absence of Apoe, we decided to assess whether the fibrillar amyloid burden was significantly altered by Apoe deficiency using X-34, which labels amyloid structures (Styren et al., 2000).”
Zhou, X., Stemme, S., & Hansson, G. K. (1996) · Europe PMC (PubMed Central) · Cited by 249
Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes
Chung, W.-S., Verghese, P. B., Chakraborty, C., Joung, J., Hyman, B. T., Ulrich, J. D., Holtzman, D. M., & Barres, B. A. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609896113 · Cited by 242 · cited 2×
“However, beyond its effect on amyloid, apoE also influences diverse processes in the brain, such as synaptogenesis, phagocytosis, BBB function, and microglial activation (Mauch et al., 2001; Bell et al., 2012; Butovsky et al., 2015; Chung et al., 2016; Krasemann et al., 2017; Shi et al., 2017).”
Self-citationSerrano-Pozo, A., Muzikansky, A., Gómez-Isla, T., Growdon, J. H., Betensky, R. A., Frosch, M. P., & Hyman, B. T. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182933788 · Cited by 226
Huynh, T.-P. V., Davis, A. A., Ulrich, J. D., & Holtzman, D. M. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075481 · Cited by 210 · cited 4×
“ApoE has previously been shown to influence the rate of monomeric Aβ clearance from the brain interstitial fluid in an isoform-dependent manner and to influence the kinetics of amyloid formation in vitro (Bell et al., 2007; Deane et al., 2008; Huynh et al., 2017a).”
InfluentialSelf-citationAge-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis
Huynh, T.-P. V., Liao, F., Francis, C. M., Robinson, G. O., Serrano, J. R., Jiang, H., Roh, J., Finn, M. B., Sullivan, P. M., Esparza, T. J., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.11.014 · Cited by 209 · cited 3×
“ApoE has previously been shown to influence the rate of monomeric Aβ clearance from the brain interstitial fluid in an isoform-dependent manner and to influence the kinetics of amyloid formation in vitro (Bell et al., 2007; Deane et al., 2008; Huynh et al., 2017a).”
Self-citationKlingstedt, T., Åslund, A., Simon, R. A., Johansson, L. B. G., Mason, J. J., Nyström, S., Hammarström, P., & Nilsson, K. P. R. (2011) · Organic & Biomolecular Chemistry · doi:10.1039/c1ob05637a · Cited by 193 · cited 3×
“…q-FTAA stains only mature fibrillar Aβ deposits that are also recognized by conventional amyloid ligands, such as thioflavin T and X-34, whereas h-FTAA detects a broader subset of disease-associated protein aggregates (Klingstedt et al., 2011, 2013; Nyström et al., 2013; Magnusson et al., 2014).”
InfluentialSelf-citationHuman APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition
Rodriguez, G. A., Tai, L. M., LaDu, M. J., & Rebeck, G. W. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-111 · Cited by 193 · cited 1×
“ApoE4 and apoE2 exhibited increased numbers of plaque-associated microglia within certain cortical regions of 5xFAD mice compared with apoE3 (Rodriguez et al., 2014).”
Grainger, D. J., Reckless, J., & McKilligin, E. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.10.6366 · Cited by 183 · cited 1×
“This may be attributable to increases in peripheral TNF-α expression in Apoe−/− mice, since TNF-α is transported across the blood–brain barrier (BBB; Gutierrez et al., 1993; Grainger et al., 2004).”
ApoE deficiency leads to a progressive age-dependent blood-brain barrier leakage
Hafezi-Moghadam, A., Thomas, K. L., & Wagner, D. D. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00563.2005 · Cited by 149 · cited 1×
“Previous studies indicate that Apoe−/− mice have age-dependent BBB dysfunction, which leads to extravasation of peripheral proteins with neurotoxic consequences (Hafezi-Moghadam et al., 2007; Bell et al., 2012).”
ApoE immunoreactivity and microglial cells in Alzheimer’s disease brain
Uchihara, T., Duyckaerts, C., He, Y., Kobayashi, K., Seilhean, D., Amouyel, P., & Hauw, J.-J. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11763-m · Cited by 131 · cited 2×
“The proximity of microglia versus astrocytes to plaques could indicate a unique role for microglial expressed apoE in the immune response to AD pathology (Uchihara et al., 1995).”
BackgroundEvidence for Age-Dependent in Vivo Conformational Rearrangement within Aβ Amyloid Deposits
Nyström, S., Psonka-Antonczyk, K. M., Ellingsen, P. G., Johansson, L. B. G., Reitan, N., Handrick, S., Prokop, S., Heppner, F. L., Wegenast-Braun, B. M., Jucker, M., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb4000376 · Cited by 111 · cited 5×
“A previous study demonstrated that a combination of two LCOs, q-FTAA and h-FTAA, can be used for spectral assignment of distinct aggregated Aβ morphotypes (Nyström et al., 2013).”
InfluentialSelf-citationIrizarry, M. C., Cheung, B. S., Rebeck, G. W., Paul, S. M., Bales, K. R., & Hyman, B. T. (2000) · Acta Neuropathologica · doi:10.1007/s004010000263 · Cited by 93 · cited 3×
“ApoE modifies Aβ deposition Previous studies in human APP transgenic mice, PDA PP and Tg2576, found that Apoe deficiency significantly reduced both total and fibrillar Aβ deposition (Bales et al., 1997, 1999; Holtzman et al., 2000; Irizarry et al., 2000).”
Katsouri, L., & Georgopoulos, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021880 · Cited by 72 · cited 1×
“However, more recently developed aggressive mouse models of amyloid deposition exhibit modest fibrillar amyloid deposition in the absence of apoE (Katsouri and Georgopoulos, 2011).”
Magnusson, K., Simon, R. A., Sjölander, D., Sigurdson, C. J., Hammarström, P., & Nilsson, K. P. R. (2014) · Prion · doi:10.4161/pri.29239 · Cited by 71 · cited 4×
“q-FTAA stains only mature fibrillar Aβ deposits that are also recognized by conventional amyloid ligands, such as thioflavin T and X-34, whereas h-FTAA detects a broader subset of disease-associated protein aggregates (Klingstedt et al., 2011, 2013; Nyström et al., 2013; Magnusson et al., 2014).”
InfluentialSelf-citationKlingstedt, T., Blechschmidt, C., Nogalska, A., Prokop, S., Häggqvist, B., Danielsson, O., Engel, W. K., Askanas, V., Heppner, F. L., & Nilsson, K. P. R. (2013) · ChemBioChem · doi:10.1002/cbic.201200731 · Cited by 60 · cited 1×
“…q-FTAA stains only mature fibrillar Aβ deposits that are also recognized by conventional amyloid ligands, such as thioflavin T and X-34, whereas h-FTAA detects a broader subset of disease-associated protein aggregates (Klingstedt et al., 2011, 2013; Nyström et al., 2013; Magnusson et al., 2014).”
Self-citationSu, Z., Li, Y., James, J. C., MCDUFFIE, M. J., Matsumoto, A. H., Helm, G. A., Weber, J. L., Lusis, A. J., & Shi, W. (2005) · Genetics · doi:10.1534/genetics.105.051912 · Cited by 51 · cited 1×
“Interestingly, the background strain can strongly influence the degree of atherosclerosis that develops in Apoe−/− mice; C57BL/6 mice exhibit more robust atherosclerosis pathology than C3H mice (Su et al., 2006).”
Apolipoprotein E mediation of neuro-inflammation in a murine model of multiple sclerosis
Shin, S., Walz, K. A., Archambault, A. S., Sim, J., Bollman, B. P., Koenigsknecht-Talboo, J., Cross, A. H., Holtzman, D. M., & Wu, G. F. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.03.010 · Cited by 32 · cited 1×
“Reductions in microgliosis were also observed in the experimental autoimmune encephalomyelitis model of multiple sclerosis and reduced inflammation and neurodegeneration were observed in an Apoe-deficient model of tauopathy (Shin et al., 2014; Shi et al., 2017).”
Self-citationDiagnostic criteria for primary progressive mutiple sclerosis: a position paper.
(2000) · Pure Amsterdam UMC · doi:10.1002/1531-8249(200006)47:6 · Cited by 2
Self-citation
Cited by
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
“Since ApoE promotes plaque-associated microgliosis resulting in plaque compaction and reduced neuritic dystrophy (Ulrich et al., 2018), therapeutically reducing ApoE levels may also have unexpected effects on the innate immune response to established plaques.”
Self-citationApolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425
APOE and Alzheimer’s disease: Advances in genetics, pathophysiology, and therapeutic approaches
Serrano-Pozo, A., Das, S., & Hyman, B. T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30412-9 · Cited by 1,037
Sala Frigerio, C., Wolfs, L., Fattorelli, N., Thrupp, N., Voytyuk, I., Schmidt, I., Mancuso, R., Chen, W.-T., Woodbury, M. E., Srivastava, G., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.099 · Cited by 926
“Lack of Apoe expression did not alter the global amyloid burden (Figures 6B, 6D, and 6E); however, it caused a significant decrease in the amounts of Metoxy-XO4-stained amyloid (Figure 6F), as previously reported for other Apoenull AD mouse models (Holtzman et al., 2000; Irizarry et al., 2000; Krasemann et al., 2017;…”
ResultApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756
“Interestingly, studies have demonstrated that apoE-deficient mice show reduced microglial reactivity to plaques [105, 116, 117], suggesting that apoE may be necessary for the microglial response to amyloid aggregation.”
Background
Metadata
- Authors
- Ulrich, J. D., Ulland, T. K., Mahan, T. E., Nyström, S., Nilsson, K. P., Song, W. M., Zhou, Y., Reinartz, M., Choi, S., Jiang, H., Stewart, F. R., Anderson, E., Wang, Y., Colonna, M., & Holtzman, D. M.
- Affiliations
- Washington University in St. Louis (US)
- Linköping University (SE)
- Radboud University Nijmegen (NL)
- Eli Lilly (United States) (US)
- Corresponding author
- Colonna, Marco
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2018-02-26
- Volume
- 215
- Issue
- 4
- Pages
- 1047-1058
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC5881464
- OpenAlex
- W2790949074
- Cited by
- 297
- References
- 58
- Citations by year
- 2026: 26 · 2025: 29 · 2024: 41 · 2023: 46 · 2022: 44 · 2021: 33 · 2020: 31 · 2019: 32 · 2018: 15
- FWCI
- 19.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- National Institutes of Health (AG047644)
- JPB Foundation
- Cure Alzheimer’s Fund
- NIH (RF1AG05148501, 5-T32CA009547-30)
- Donors Cure Foundation (CCAD201703)
- Eli Lilly and Company
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Keywords
- apolipoprotein E, amyloid-beta, amyloid plaques, microglia, Alzheimer's disease, innate immune response, microglial activation, ApoE-deficient mice, dystrophic neurites
- MeSH terms
- Alzheimer Disease, Amyloid, Animals, Apolipoproteins E, Brain, Disease Models, Animal, Humans, Immunity, Innate, Mice, Transgenic, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Microglia, Mice, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.